Nephrology in 30 days pdf download

This process takes up to days to complete. One should admit the symptomatic patient to the intensive care unit and precautions should be taken to ensure a secure airway. Serum electrolytes are monitored every 2 hours. Water restriction alone has no role in the management of the symptomatic patient since it corrects the serum sodium concentration too slowly. In the absence of severe symptoms, serum sodium concentration is raised more slowly 0. A variety of formulas can be used to calculate the sodium requirement.

They allow one to calculate the amount of sodium that would need to be added or water that would need to be removed in order to return the serum sodium concentration to normal. Although both sodium and water have either been removed or added in the process of generating the hyponatremia, these formulas work well in clinical practice. In the hypovolemic patient one discontinues diuretics, corrects gastrointestinal fluid losses, and expands the ECF with normal saline.

Replacing the ECF volume deficit is important because this eliminates the stimulus for the nonosmotic release of AVP and leads to the production of a maximally dilute urine. If vomiting, diarrhea, or diuretics caused the volume depletion, potassium deficits also must be corrected.

The following example illustrates the degree of reduction in total body water required to restore the serum sodium concentration to normal. A kg man has a total body water of 45 L and a serum sodium concentration of meq!

The formula below is used to calculate the desired total body water. Subtracting the desired from the current total body water reveals that 8. Fluid restriction rarely increases the serum sodium concentration by more than 1. The hypervolemic patient is managed with salt and water restriction. Negative water balance is achieved if daily fluid intake is less than the excretion of free water in urine.

If congestive heart failure is the cause, an increase in cardiac output will suppress AVP release. Common management errors in the treatment of the hyponatremic patient and recommendations include the following: 1.

A fear of CPM often leads to a delay in correction or too slow a rate of correction of hyponatremia. Neurologic sequelae are far more commonly related to too slow a rate of correction rather than rapid correction. Hypertonic saline should be employed in hyponatremic encephalopathy. Every effort should be made to prevent seizure and respiratory arrest, once these sequelae develop permanent neurologic injury is the rule. Magnetic resonance imaging is the study of choice to diagnose CPM but may take up to weeks after the onset of signs and symptoms to show characteristic abnormalities.

Be aware of patients at high risk for hyponatremic encephalopathy such as premenopausal women in the postoperative setting. Postoperative patients should never receive free water. The intravenous fluid of choice in this setting is normal saline or Ringers lactate. Electrolytes are monitored daily. Normal saline administration in this setting results in a further fall in serum sodium concentration.

The kidney is capable of generating free water from normal saline. This results in the generation of rnL of free water the remainder of the 1 L given and a further fall in serum sodium concentration.

The morbidity and mortality of hyponatremia are related to neurologic injury that occurs as a result of hyponatremic encephalopathy or improper therapy too rapid or overcorrection. The major factor contributing to neurologic injury is hypoxia. Premenopausal w omen are at highest risk. Treatment is dependent on the acuity and severity of hyponatremia, and the patient's ECF volume status. Postoperative patients should not receive free water.

It occurs when AVP concentration or effect is decreased or water intake is less than insensible, gastrointestinal and renal water losses. Therefore, hypernatremia results when there is a failure to take in enough free water in either the presence or absence of a urinary concentrating defect. This is most commonly seen in those patients who depend on others for access to water or lack thirst sensation. Infrequently, hypernatremia results from salt ingestion or administration of hypertonic saline solutions.

Figure 3. The rise in serum osmolality stimulates thirst and AVP release from the posterior pituitary. Stimulation of thirst results in increased free water intake. Arginine vasopressin binds to its receptor in the basolateral membrane of collecting duct and stimulates water reabsorption. Since the average daily solute load is approximately mOsm, this solute is excreted in as little as 0.

Note that even under maximal antidiuretic conditions, one must drink at least this volume of water per day in order to maintain water balance. Thirst is an integral component of the water regulatory system. The normal function of the renal concentrating mechanism requires that its various components be intact.

These include the fallowing: 1. The transporter serves the dual process of diluting tubular fluid and rendering the interstitium progressively hypertonic from cortex to papilla. AVP secretion. Arginine vasopressin is a nonapeptlde produced by neurons originating in the supraoptic and paraventricular nuclei of the hypothalamus. These neurons cross the pituitary stalk and terminate in the posterior pituitary. Arginine vasopressin is processed and stored in neurosecretory granules along with neurophysin and copeptin.

Abnormalities in the renal concentrating process obligate excretion of a larger volume of urine to maintain solute balance, e. Failure to replace these water losses orally leads to progressive water depletion and hypernatremia. Hypematremia results when there is a failure to take in enough free water in either the presence or absence of a concentrating defect.

It is most commonly seen in those who depeod on others for access to water or who lack thirllt. Normal concentrating mechanism function requires the ability to generate a hypertonic interstitium, AVP secretion, and normal coll. Central DI may be idiopathic or secondary to head trauma, surgery, or neoplasm. Urine volume ranges from 3 to 15 IJday.

Patients tend to be young with nocturia and a preference for cold water. Treatment consists of administering AVP. The best therapy is long-acting, nasally administered dD-AVP. An important point is that thirst is stimulated by the increased p osm so effectively that serum sodium concentration is only slightly elevated and the most common clinical presentation is polyuria.

Psychogenic polydipsia also presents with polyuria; however, the serum sodium concentration is often mildly decreased rather than increased. One-third to one-half of central DI cases are idiopathic. A lymphocytic infiltrate is present in the posterior pituitary and pituitary stalk.

Some of these patients have circulating antibodies directed against vasopressin-producing neurons. Familial central DI is rare and inherited in three ways. The most common is an autosomal dominant disorder resulting from mutations in the coding region of the AVP gene. The mutant protein fails to fold properly and accumulates in the endoplasmic reticulum resulting in neuronal death. Because neurons die slowly vasopressin deficiency is not present at birth but develops over years.

It often gradually progresses from a partial to complete defect. A similar clinical presentation is seen with X-linked inheritance, although the evidence for this mode of inheritance is weak. Autosomal recessive central DI is a very rare disorder caused by a single amino acid substitution resulting in the production of an AVP with little to no antidiuretic activity.

It is caused by a number of mutations in the V2 receptor. Aquaporin-2 gene mutations also result in nephrogenic DI and may be inherited in an autosomal dominant or recessive fashion.

In dominant cases heterotetramers form between mutant and wild type aquaporin-2 water channels that are unable to traffic to the plasma membrane. This usually results in complete resistance to the effects of AVP. Acquired nephrogenic DI is much more common but often less severe. Chronic renal failure, hypercalcemia, lithium treatment, obstruction, and hypokalemia are its causes. Aquaporin-2 expression in principal cells of the collecting duct is markedly reduced. Lithium is the most common treatment for manic-depressive psychosis.

Approximately 0. Both hypokalemia and hypercalcemia are associated with a significant downregulation of aquaporin Aquaporin-2 expression normalizes after 7 days of a normal potassium diet. A number of drugs may cause a renal concentrating defect.

Ethanol and phenytoin impair AVP release resulting in a water diuresis. Thus, a concentrating defect inability to conserve water can be secondary to a lack of AVP, unresponsiveness to AVP, or renal tubular dysfunction. Other specific causes and mechanisms for concentrating defects include sickle cell anemia or trait medullary vascular injury , excessive water intake or primary polydipsia decreased medullary tonicity , severe protein restriction decreased medullary urea , and a variety of disorders affecting renal medullary vessels and tubules.

Vasopressinase is an enzyme produced by the placenta that degrades AVP and oxytocin. It appears in plasma of women early in pregnancy and increases in activity throughout gestation. After delivery, which is curative due to loss of the placenta, vasopressinase rapidly becomes undetectable. Although only case reports of diabetes insipidus from vasopressinase are published to date, it is unclear how frequently this condition actually occurs.

These patients often respond to desmopressin dD-AVP , which is not degraded by vasopressinase. This results in neuromuscular irritability with twitches, hyperreflexia, seizures, coma, and death. Two-thirds of survivors have permanent neurologic injury.

Hypernatremia is often a marker of serious underlying disease. Of note, the brain protects itself from the insult of hypernatremia by increasing its own osmolality, in part due to increases in free amino acids.

The mechanism is unclear, but the phenomenon is referred to as the generation of "idiogenic osmoles. Diabetes insipidus may be central due to decreased pituitary production and release of AVP or nephrogenic secondary to decreased renal responsiveness to AVP. Central DI is idiopathic or secondary to head trauma, surgery, or neoplasm. Acquired nephrogenic DI occurs most commonly with lithium administration. Aquaporin-2 expression in principal cells of collecting duct is markedly reduced.

A variety of drugs cause renal concentrating defects. Symptoms of hypernatremia result from a shift of water out of brain cells. In chronic hypernatremia the brain generates "idiogenic osmoles" that reduce the gradient for water movement. Patients with hypernaUemia can also be categorized based on ECP volume status. The majority have decreased or normal ECP volume total body sodium. Many disorders may result in hypernatremia; however, decreased thirst, inability to gain access to water, and drugs are the most common causes Figure 3.

A high serum sodium concentration results from free water loss that is not compensated for by an increase in free water intake. Free water loss may be renal or extrarenal in origin. Extrarenal losses originate from skin, respiratory tract, or from the gastrointestinal tract. Renal losses are the result of a solute osmotic or water diuresis. A solute or osmotic diuresis most commonly results from excretion of glucose in uncontrolled diabetes mellitus. A water diuresis is secondary to central or nephrogenic DI.

If thirst is intact, patients with renal losses present with the chief complaint of polyuria, defined as the excretion of more than 3 L of urine daily. An increased serum sodium concentration is a potent stimulus for thirst and AVP release.

After a thorough history and physical examination are performed the clinician must answer several questions in the hypernatremic patient. First, is thirst intact? Second, if the patient is thirsty, is he capable of getting to water?

The next step is to evaluate the hypothalamic-pituitary-renal axis. This involves an examination of urine osmolality. If urine osmolality is greater than mOsm! A urine osmolality less than plasma indicates that the kidney is the source of free water loss as a result of either central or nephrogenic DI.

These disorders are differentiated by the response to exogenous AVP. Hither 5 units of aqueous vasopressin subcutaneously or 10! Urine osmolality in the intermediate range mOsmlkg may be secondary to psychogenic polydipsia, an osmotic diuresis, and partial central or nephrogenic Dl.

Psychogenic polydipsia is generally associated with a mildly decreased rather than increased serum sodium concentration. Partial central and nephrogenic DI may require a water deprivation test to distinguish. In the water deprivation test water is prohibited and urine volume and osmolality measured hourly and serum sodium concentration and osmolality every 2 hours.

In the last two circumstances exogenous vasopressin is administered and the urine osmolality and volume measured. In partial nephrogenic DI the urine osmolality may increase slightly but generally remains below serum osmolality. Total osmolar excretion is calculated by multiplying the urine osmolality by the urine volume in a hour collection.

Hypernatremia occurs most commo nly in association with hypovolemia. The euvolemic patient is only mildly hypernatremic but will complain of polyuria. Free water loss is renal or extrarenal in o rigin.

The clinician should first examine whether thirst and access to free water are intact. The next step is to evaluate the hypothalamicpituitary-renal axis. This involves an examination of the urine osmolality. A urine osmolality less than plasma indicates that the kidney is the source of free water loss from either central or nephrogenic DI. These disorders are differentiated by the response of urine osmolality to exogenous AVP. When restoring plasma tonicity to normal and correcting sodium imbalances, sodium may need to be added or removed while providing water.

A formula to calculate the total amount of water needed to lower serum sodium concentration from one concentration to another can be used. Water deficits are corrected preferably with increased oral intake or with intravenous administration of hypotonic solution. The formula above calculates the amount of free water replacement needed at the time the patient is first seen. If urine volume is high or urine osmolality low then one must add ongoing renal free water losses to the replacement calculation.

In order to determine ongoing renal free water losses one must calculate the electrolyte-free water clearance. For this purpose urine is divided into two components: an isotonic component the volume needed to excrete sodium and potassium at their concentration in serum ,and an electrolytefree water component. A 70 kg male with a history of nephrogenic DI is found unconscious at home and is brought to the Emergency Department.

If water were given at this rate in the form of D5W, serum sodium concentration would increase not decrease. The reason for this is that the replacement calculation did not include the large ongoing free water loss in urine.

Treatment is also directed at the underlying disorder. In the patient with nephrogenic DI significant hypernatremia will not develop unless thirst is impaired or the patient lacks access to water. The goal of treatment is to reduce urine volume and renal free water excretion.

As discussed earlier, urine volume is equal to osmolar excretion or intake they are the same in the steady state divided by the urine osmolality.

Urine volume can be reduced by decreasing osmolar intake with protein or salt restriction or by increasing urine osmolality. Thiazide diuretics inhibit urinary dilution and increase urine osmolality. Nonsteroidal anti-inflammatory agents NSAIDs by inhibiting renal prostaglandin synthesis increase concentrating ability. Prostaglandins normally antagonize the action of AVP. Their effects are partially additive to those of thiazide diuretics. Electrolyte disturbances such as hypokalemia or hypercalcemia should be corrected.

Early in the course of lithium-induced nephrogenic DI, amiloride may be of some benefit. Amiloride prevents the entry of lithium into the cortical collecting duct principal cell and can limit its toxicity. Table 3. Intranasal desmopressin is most commonly used. The initial dose is 5 f,Lg at bedtime and is titrated upward to a dose of f,Lg once or twice daily.

Desmopressin can also be administered orally. In general a 0. Serum sodium concentration must be followed carefully during dose titration to avoid hyponatremia. Desmopressin is expensive. As a consequence drugs that increase AVP release or enhance its effect can be added to reduce cost. These drugs can also be used in patients with partial central DI. Chlorpropamide and carbamazepine enhance the renal action of AVP. Clofibrate may increase AVP release. Treatment of hypernatremia is directed at restoring plasma tonicity to normal, correcting sodium imbalances, and providing specific treatment directed at the underlying disorder.

Water deficits are restored slowly to avoid sudden shifts in brain cell volume. If urine volume is high or urine osmolality low then one must account for ongoing renal free water losses. In the patient with nephrogenic DI urine volume is reduced by decreasing osmolar intake with protein or salt restriction or by increasing urine osmolality with thiazide diuretics.

Additional Reading Adrogue, HJ. N Englj Med , Adrogue, H. Bedford, ]. Aquaporin expression in normal human kidney and in renal disease. Calakos, N. Cortical MRI findings associated with rapid correction of hyponatremia. Neurology , Fraser, C. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am]Med , Goldszmidt, M. Cltn Nephrol, Lancet , Milionis, H. The hyponatremic patient: a systematic approach to laboratory diagnosis.

CMA] , Moran, S. The variable hyponatremic response to hyperglycemia. West] Med , Nielsen, S. Aquaporins in the kidney: from molecules to medicine. Physlol Rev , Zarinetchi, F. Evaluation and management of severe hyponatremia. Adv Intern Med , Perazella Diuretics Recomm. What is the difference between diuresis and natriuresis? How do diuretics reach their site of action? Where do diuretics act in the nephron? Which diuretics act in the proximal tubule and what is their mechanism of action?

What transporter in the loop of Henle reabsorbs NaCl? How do diuretics that act in cortical collecting duct CCD induce natriuresis? What are some of the common adverse effects of various diuretics? What is diuretic resistance and how does one assess for the cause of resistance? How does diuretic resistance develop in the setting of chronic loop diuretic therapy? How does one treat various causes of diuretic resistance? Diuretics were initially described as a useful therapy to reduce edema in the sixteenth century.

The first agent known to increase urine output was mercurous chloride. These changes in urine were considered an adverse effect of drugs intended for other purposes. Targeted disruption of various renal transporters was not part of the development of these drugs as the mechanism of transport was unknown; rather diuretics were developed empirically. Diuretics are the most commonly prescribed medications in the United States.

They are used to treat a variety of clinical disease states including hypertension, edema, congestive heart failure, hyperkalemia, and hypercalcemia. To understand the actions of diuretics, one must first appreciate renal handling of sodium and water.

Sodium intake is balanced by the renal excretion of sodium. A normal glomerular filtration rate GFR is important for the optimal excretion of sodium and water. Following formation and passage of glomerular ultrafiltrate into Bowman's space, delivery of sodium and water to the proximal tubule is the first site of tubular handling. Along the nephron sodium is reabsorbed by several different transport mechanisms.

Mistakes are made when there is improper understanding of the patient's volume and electrolyte status. Hypovolemia is a common problem in hospitalized patients, especially those in critical care units. It can occur in a variety of clinical settings Every physician and physician in training must master the ability to use intravenous solutions for the expansion of the intravascular and ECF volume. In one study, inadequate volume resuscitation was viewed as the most common management error in patients who died in the hospital after admission for treatment of injuries.

It Is distributed between intracellular fluid ICF The ECF compartment is further subdivided into intravascular and interstitial spaces.

The ECF and ICF are in osmotic equilibrium, and if an osmotic gradient is established, water will flow from a compartment of low osmolality to a compartment of high osmolality.

For example, if a solute is added to the ECF such as glucose that raises its osmolality, water will flow out of the ICF until the osmotic gradient is dissipated. Water movement into and out of ceUs, particularly in the brain, with resultant cell swelling or shrinking is responsible for the symptoms of hyponatremia and hypematremia.

Urea distributes rapidly across ceU membranes and equilibrates throughout total body water and is with one exception, an ineffective osmole. Equilibration of urea across the blood-brain barrier can take several hours. If urea is rapidly removed from the ECF with the initiation of hemodialysis in a patient with end-stage renal disease, the potential exists for the development of "dialysis disequllibrlum syndrome. As urea concentration falls during hemodialysis a transient osmotic gradient Figure5.

Total body warer consisal of intta. Starlint s fon::e. Forces acting to move fluid into the capillary are the intrava. Fluid in the inteistitial space drains back to the venous system via lymphatics. Edema may be localized due to vascular or lymphatic injury or it may be generalized as in congestive heart failure. LR is the lymphatic return. In CHF, for example, the Pc increases. In cirrhosis, the Pc increases secondary to portal hypertension and the nc declines.

The major specific causes of edema, classified according to the major mechanism s responsible are shown in Table 5. The final common pathway maintaining generalized edema is renal retention of excess sodium and water.

It is distributed between ICF The serum sodium concentration is a function of the ratio of sodium to water and does not correlate with ECF volume, which is a function of total body sodium.

Starling's forces govern movement of water between intravascular and interstitial spaces. The most common abnormalities leading to edema formation are an increase in capillary hydrostatic pressure or a decrease in capillary oncotic pressure.

The clinician can choose between a wide array of crystalloids and colloids. Crystalloid solutions consist of water and dextrose and may or may not contain other electrolytes. The composition varies depending on the type of solution. Some of the more commonly used crystalloid solutions and their components are shown in Table 5. Ringer's lactate is used more commonly on surgical services and normal saline on medical services.

Colloid solutions consist of large molecular weight molecules such as proteins, carbohydrates, or gelatin. Colloids increase osmotic pressure and remain in the intravascular space longer compared to crystalloids. Osmotic pressure is proportional to the number of particles in solution.

Colloids do not readily cross normal capillary walls and result in fluid translocation from interstitial space to intravascular space. Colloids are referred to as monodisperse, like albumin, if the molecular weight is uniform, or polydisperse, if there is a range of different molecular weights, as with starches.

This is important because molecular weight determines the duration of colloidal effect in the intravascular space. Smaller molecular weight colloids have a larger initial oncotic effect but are rapidly renally excreted and, therefore, have a shorter duration of action. Hydroxyethyl starch HES , dextran, and albumin are the most commonly used colloids.

Gelatins are not commercially available in the United States. Hydroxyethyl starch is a glucose polymer derived from amylopectin. Hydroxyethyl groups are substituted for hydroxyl groups on glucose. The substitution results in slower degradation and increased water solubility.

Naturally occurring starches are degraded by circulating amylases and are insoluble at neutral pH. Hydroxyethyl starch has a wide molecular weight range. Duration of action is dependent on rates of elimination and degradation. Smaller molecular weight species are eliminated rapidly by the kidney.

The rate of degradation is determined by the degree of substitution the percentage of glucose molecules having a hydroxyethyl group substituted for a hydroxyl group. Substitution occurs at positions C2, C3, and C6 of glucose and the location of the hydroxyethyl group also affects the rate of degradation.

Hetastarch is a HES with a large molecular weight kDa , slow elimination kinetics, and is associated with an increase in bleeding complications after cardiac and neurosurgery.

The larger the molecular weight and the slower the rate of elimination, the more likely that HES will cause clinically significant bleeding. Newer HES preparations with lower molecular weights and more rapid elimination kinetics may be associated with fewer complications.

Hetastarch use is also associated with an increased risk of acute renal failure in septic patients and in brain-dead kidney donors. Given these findings, Hetastarch cannot be recommended in patients with impaired kidney function. The threshold level of glomerular filtration rate below which Hetastarch should be avoided is unknown.

A comparison between albumin and Hetastarch is shown in Table 5. One liter of Hetastarch will initially expand the intravascular space by mL. Dextrans are glucose polymers with an average molecular weight of kDa produced by bacteria grown in the presence of sucrose. In addition to expanding the intravascular volume, dextrans also have anticoagulant properties.

Several studies show that they decrease the risk of postoperative deep venous thrombosis and pulmonary embolism.

Dextran infusion decreases levels of von Willebrand factor and factor VIII:c more than can be explained by plasma dilution alone. Dextrans also enhance fibrinolysis and protect plasmin from the inhibitory effects of a-2 antiplasmin.

In clinical studies comparing dextran to unfractionated heparin, low-molecular weight heparin, and heparinoids in the prophylaxis of postoperative deep venous thrombosis, dextran was associated with increased blood loss after transurethral resection of the prostate and hip surgery. Dextran 40 use is also associated with acute renal failure in the setting of acute ischemic stroke. Two large meta-analyses by the Cochrane Injuries group and by Wilkes and Navickis evaluated albumin as an intravascular volume expander.

The Cochrane group compared albumin to crystalloid in critically ill patients with hypovolemia, burns, and hypoalbuminemia. The authors found no evidence that albumin reduced mortality and a strong suggestion that it increased risk of death. Wilkes and Navickis showed that the relative risk of death was increased with albumin administration in patients with trauma, burns, and hypoalbuminemia but the increase in all cases was not statistically significant. Given these concerns and the higher cost of albumin compared to crystalloids and other synthetic colloids, routine use of albumin as a plasma volume expander cannot be supported.

Albumin is available in two concentrations. Advocates of colloids argue that crystalloids excessively expand the interstitial space and predispose patients to pulmonary edema. Crystalloid advocates point out that colloids are more expensive, have the potential to leak into the interstitial space in clinical conditions where capillary walls are damaged, as in sepsis, and increase tissue edema.

Despite decades of research, however, in most clinical situations there is no difference in pulmonary edema, mortality, or length of hospital stay between colloids and crystalloids. Crystalloids contain water and dextrose and may or may not contain other electrolytes. The most commonly used crystalloids are nonnal saline and Ringer's lactate. Colloid solutions consist of large molecular weight molecules. Hetastarch is associated with an increased risk of acute renal failure in septic patients and in brain-dead kidney donors.

Its use cannot be recommended in patients with impaired kidney function. Further studies are needed to establish the threshold level of glomerular filtration rate below which Hetastarch should be avoided. Given the higher cost of albumin compared to crystalloids and other synthetic colloids and the possible association with higher mortality rates, the routine use of albumin as an intravascular plasma volume expander cannot be recommended.

In critically ill patients there is no difference in pulmonary edema, mortality, or length of hospital stay with either colloid or crystalloid use.

As a general rule the fluid deficit is Lin the patient with a history of volume loss, Lin the patient with orthostatic hypotension, and Lin the septic patient Since colloids are initially confined to the intravascular space, about one-fourth of these volumes are required if colloids are used.

For most clinical indications aystalloids and colloids are equivalent. In the bleeding patient aystalloids are preferred. In the patient with total body salt and water excess CHF, cirrhosis, nephrosis colloids minimize sodium overload. Albumin should only be used in specialized situations such as large volume paracentesis. Crystalloids such as normal saline and Ringer's lactate or colloids are the replacement fluid of choice. In patients with identifiable sources of fluid loss, it is important to be aware of the electrolyte content of body fluids shown in Table 5.

Of note, sweat and gastric secretions are relatively low in sodium and potassium, whereas colonic fluids are high in potassium and bicarbonate. Normal maintenance requirements for fluids and electrolytes must also be considered and added to deficits. Insensible water losses are less in the ventilated patient breathing humidified air. Potassium should be repleted carefully in patients with chronic kidney disease. The amount of sodium and fluid replaced is based on the physical examination and clinical situation.

For most clinical indications crystalloids and colloids are equivalent. Updated to include the latest research and advances, including: New formulas for estimating glomerular filtration rate The role of WNK kinases in distal tubular sodium and potassium handling Revised hyponatremia guidelines The use of vaptans for clinical use Newly reported forms of metabolic acidosis The role FGF and Klotho play in phosphorus homeostasis Concerns about the use of erythropoietic stimulating agents Approaches to and classification of both chronic kidney disease and acute kidney injury Discussion of urinalysis and urine microscopy in the evaluation of kidney disease New forms of tubulointerstitial disease such as immunoglobulin G4 IgG4 -related disease The pathological classification of systemic lupus nephritis and other glomerular diseases The mechanisms and causes of essential and secondary forms of hypertension.

Chapters cover the physiology, biomarkers, therapeutic agents and full spectrum of these comorbidities and feature separate sections on cardiovascular and CKD evaluations, stratification of kidney transplant patients, lipid management in CKD, interventional strategies and hypertension. Leaders in cardiology, nephrology, hypertension and lipidology bring together the latest evidence with their collective clinical experience into this invaluable resource.

This textbook is an essential resource for physicians and allied professionals practicing cardiology, nephrology, students and physician trainees, to deepen their understanding of this crucial field. This concise yet comprehensive guide covers everything from history taking and urinalysis, to electrolyte management, acute kidney injury and transplantation.

It is a complete reference for the day to day, bedside, and out-patient management of all conditions dealt with by general paediatricians and specialist paediatric nephrologists. The handbook also offers advice to clinical professionals working with patients in shared care between general hospitals and specialised centres.

Paediatric Nephrology benefits from a clear, user-friendly layout, with bullet points and text boxes to highlight key information and colour plates illustrations and photographs.

This makes the book a perfect reference for use on-the-go, and easy to navigate during an emergency. The primary focus of the book is investigation and management, but in order to enable a better understanding of conditions such as fluid and electrolytes, it also discusses pathophysiology. Evidence-based recommendations are made where possible, however the authors also provide recommendations informed by their own personal experience and current best practice in areas where high quality evidence is still lacking.

Paediatric Nephrology is useful for paediatric consultants and doctors at all levels of their training, including the general paediatrician and the specialist nephrologist.

The book has a global appeal, and presents information that is applicable worldwide. This book is meant as a pragmatic text for use at the patient's bedside. You can also find all the drug and disease information. In this app, you will find all the medical books you need.

You can also download all of them in PDF format and on top of that, it is completely free. Uploaded by No1 Doctor on June 3, Internet Archive's 25th Anniversary Logo.

Search icon An illustration of a magnifying glass. User icon An illustration of a person's head and chest.